Medicenna Therapeutics Corp (MDNA) — Cash Flow-to-Debt Ratio
Medicenna Therapeutics Corp (MDNA) has a Cash Flow-to-Debt Ratio of -0.72x as of December 2025, meaning its operating cash flow of CA$-4.96 Million could theoretically repay -1% of its total liabilities (CA$6.85 Million) in one year. See financial flexibility index of Medicenna Therapeutics Corp to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medicenna Therapeutics Corp Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Medicenna Therapeutics Corp across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Medicenna Therapeutics Corp.
Annual Cash Flow-to-Debt Ratio for Medicenna Therapeutics Corp (2014–2025)
Year-by-year debt coverage analysis for Medicenna Therapeutics Corp. Check MDNA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.78x | CA$-16.49 Million | CA$9.29 Million | ▼ -52.3% |
| 2024 | -1.17x | CA$-16.26 Million | CA$13.94 Million | ▲ +35.9% |
| 2023 | -1.82x | CA$-12.66 Million | CA$6.96 Million | ▲ +79.8% |
| 2022 | -9.00x | CA$-23.58 Million | CA$2.62 Million | ▼ -141.4% |
| 2021 | -3.73x | CA$-15.31 Million | CA$4.11 Million | ▲ +23.1% |
| 2020 | -4.85x | CA$-8.95 Million | CA$1.85 Million | ▼ -55.1% |
| 2019 | -3.13x | CA$-8.04 Million | CA$2.57 Million | ▲ +31.7% |
| 2018 | -4.58x | CA$-10.12 Million | CA$2.21 Million | ▼ -390.2% |
| 2017 | -0.93x | CA$-7.31 Million | CA$7.83 Million | ▼ -27.4% |
| 2016 | -0.73x | CA$-2.57 Million | CA$3.51 Million | ▲ +75.7% |
| 2015 | -3.02x | CA$-880.32K | CA$291.87K | ▼ -304.1% |
| 2014 | -0.75x | CA$-619.44K | CA$829.89K | — |